Evaluating SLC11A2 Expression in Stage III Colon Adenocarcinoma: No Prognostic Signal but Coordinated Expression with SLC40A1

Authors

  • Ryan Brownlee The Medical College of Georgia at Augusta University
  • Shagun Dolakia
  • Mashoor Al Ahammed
  • Aditya Birla
  • Raniya Ahmad
  • Girindra Raval

DOI:

https://doi.org/10.5195/ijms.2025.4098

Keywords:

Colonic Neoplasms, solute carrier family 11, proton-coupled divalent metal ion transporters

Abstract

Background: Colon cancer is characterized by the uncontrollable growth of abnormal epithelial cells and is a leading cause of cancer-related mortality worldwide. Stage 3 colon adenocarcinoma involves local lymph nodes and has a 5 year survival rate of about 65-75%. In diseases associated with marked inflammation, expression of iron regulating genes has been shown to experience significant alterations and predict worse prognosis in some patients. Notable genes involved in this pathway include SLC11A2, HAMP, FTH1, and SLC40A1.

 

Aim: This study assessed SLC11A2’s significance for predicting overall survival in stage 3 colon adenocarcinoma followed by a gene expression correlational analysis with other iron regulating genes in patients from The Cancer Genomic Atlas COAD database.

 

Methods: TCGA was queried for clinical and STAR counts RNA gene expression data within the TCGA-COAD project. 362 patients with AJCC stage 3  primary colon adenocarcinoma were selected. STAR RNA data was normalized using variance stabilizing transformation and patients were stratified by quartiles of expression into Q1, Q2, Q3, or Q4 groups. Additionally, patients were classified as early onset (EO) or late onset (LO) if age at diagnosis was before or after 50 years old, respectively. A Kaplan-Meier overall survival (OS) curve was created comparing survival across quartiles of SLC11A2 expression with log rank analysis assessing significance. Univariate and multivariate Cox Proportional Hazards Analysis was completed for SLC11A2 expression quartile, age, gender, and race. Linear regression testing was completed to assess colinearity of SLC11A2 expression with HAMP, FTH1, and SLC40A1.

 

Results: On Kaplan-Meier analysis, SLC11A2 expression was not a significant predictor of survival at any quartile. Q2 experienced the worst survival, with all other quartiles displaying similar survival. On univariate analysis, quartiles of SLC11A2 expression were nonsignificant for OS. LO patients experienced significantly worsened survival compared to EO (7.23 HR, 1.76-29.7 95% CI, p=0.006). On multivariate analysis, SLC11A2 expression remained a nonsignificant predictor of OS. However, LO age group remained a significant predictor of worsened survival, moreso than on univariate analysis (13.3 HR, 3.04-58.2 95% CI, p<0.001). Race became a significant survival predictor with African American patients surviving worse than white patients (2.07 HR, 1.15-3.70 95% CI, p=0.015). On correlational analysis, SLC11A2 and SLC40A1 showed a significant positive expression correlation with no other genes showing significance (r=0.36, p<0.001).

 

 

 

Conclusion: Regardless of SLC11A2 expression, overall survival in stage 3 colon adenocarcinoma is mediated by age and race. SLC11a2 does not appear to be a significant gene in predicting prognosis in stage 3 of this cancer. SLC40a1 and slc11a2 display a significant positive expression correlation. After accounting for SLC11A2 expression, age, and gender, African American and LO patients experience significantly worsened OS.

 

Downloads

Published

2025-12-31

How to Cite

Brownlee, R., Dolakia, S., Al Ahammed, M., Birla, A., Ahmad, R., & Raval, G. (2025). Evaluating SLC11A2 Expression in Stage III Colon Adenocarcinoma: No Prognostic Signal but Coordinated Expression with SLC40A1. International Journal of Medical Students, 13, S246. https://doi.org/10.5195/ijms.2025.4098

Issue

Vol 13. (2025): Supplement 1

Section

Abstracts of the WCMSR

Categories

License

Copyright (c) 2025 Ryan Brownlee, Shagun Dolakia, Mashoor Al Ahammed, Aditya Birla, Raniya Ahmad, Girindra Raval

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

  1. The Author retains copyright in the Work, where the term “Work” shall include all digital objects that may result in subsequent electronic publication or distribution.
  2. Upon acceptance of the Work, the author shall grant to the Publisher the right of first publication of the Work.
  3. The Author shall grant to the Publisher and its agents the nonexclusive perpetual right and license to publish, archive, and make accessible the Work in whole or in part in all forms of media now or hereafter known under a Creative Commons Attribution 4.0 International License or its equivalent, which, for the avoidance of doubt, allows others to copy, distribute, and transmit the Work under the following conditions:
    1. Attribution—other users must attribute the Work in the manner specified by the author as indicated on the journal Web site; with the understanding that the above condition can be waived with permission from the Author and that where the Work or any of its elements is in the public domain under applicable law, that status is in no way affected by the license.
    2. The Author is able to enter into separate, additional contractual arrangements for the nonexclusive distribution of the journal's published version of the Work (e.g., post it to an institutional repository or publish it in a book), as long as there is provided in the document an acknowledgment of its initial publication in this journal.
    3. Authors are permitted and encouraged to post online a prepublication manuscript (but not the Publisher’s final formatted PDF version of the Work) in institutional repositories or on their Websites prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. Any such posting made before acceptance and publication of the Work shall be updated upon publication to include a reference to the Publisher-assigned DOI (Digital Object Identifier) and a link to the online abstract for the final published Work in the Journal.
    4. Upon Publisher’s request, the Author agrees to furnish promptly to Publisher, at the Author’s own expense, written evidence of the permissions, licenses, and consents for use of third-party material included within the Work, except as determined by Publisher to be covered by the principles of Fair Use.
    5. The Author represents and warrants that:
      1. the Work is the Author’s original work;
      2. the Author has not transferred, and will not transfer, exclusive rights in the Work to any third party;
      3. the Work is not pending review or under consideration by another publisher;
      4. the Work has not previously been published;
      5. the Work contains no misrepresentation or infringement of the Work or property of other authors or third parties; and
      6. the Work contains no libel, invasion of privacy, or other unlawful matter.
    6. The Author agrees to indemnify and hold Publisher harmless from the Author’s breach of the representations and warranties contained in Paragraph 6 above, as well as any claim or proceeding relating to Publisher’s use and publication of any content contained in the Work, including third-party content.

Enforcement of copyright

The IJMS takes the protection of copyright very seriously.

If the IJMS discovers that you have used its copyright materials in contravention of the license above, the IJMS may bring legal proceedings against you seeking reparation and an injunction to stop you using those materials. You could also be ordered to pay legal costs.

If you become aware of any use of the IJMS' copyright materials that contravenes or may contravene the license above, please report this by email to contact@ijms.org

 

Infringing material

If you become aware of any material on the website that you believe infringes your or any other person's copyright, please report this by email to contact@ijms.org